GenoChemetic strategy for derivatization of the violacein natural product scaffold
MetadataShow full item record
Natural products and their analogues are often challenging to synthesize due to their complex scaffolds and embedded functional groups. Solely relying on engineering the biosynthesis of natural products may lead to limited compound diversity. Integrating synthetic biology with synthetic chemistry allows rapid access to much more diverse portfolios of xenobiotic compounds, which may accelerate the discovery of new therapeutics. As a proof-of-concept, by supplementing an Escherichia coli strain expressing the violacein biosynthesis pathway with 5-bromo-tryptophan in vitro or tryptophan 7-halogenase RebH in vivo, six halogenated analogues of violacein or deoxyviolacein were generated, demonstrating the promiscuity of the violacein biosynthesis pathway. Furthermore, 20 new derivatives were generated from 5-brominated violacein analogues via the Suzuki–Miyaura cross-coupling reaction directly using the crude extract without prior purification. Herein we demonstrate a flexible and rapid approach to access a diverse chemical space that can be applied to a wide range of natural product scaffolds.
Lai , H-E , Obled , A M C , Chee , S M , Morgan , R M , Lynch , R , Sharma , S V , Moore , S J , Polizzi , K M , Goss , R J M & Freemont , P S 2021 , ' GenoChemetic strategy for derivatization of the violacein natural product scaffold ' , ACS Chemical Biology , vol. Articles ASAP . https://doi.org/10.1021/acschembio.1c00483
ACS Chemical Biology
Copyright © 2021 The Authors. Published by American Chemical Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
DescriptionH.E.L. was supported by an Imperial College President’s Ph.D. Scholarship. We thank UKRI EPSRC (EP/K038648/1, EP/L011573/1 to P.S.F.) and the European Union’s Seventh Framework Programme (FP7/2007–2013/ERC grant agreement no. 614779 GenoChemetics to R.J.M.G.) for funding. A.M.C.O. receives funding from EPSRC CRITICAT, EP/L016419/1.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.